Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment Trial-Reference-Cited by-同舟云学术

Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment Trial

Published:2018-01-12 Issue:8 Volume:217 Page:1298-1308
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Chen Ingrid¹²,Diawara Halimatou³,Mahamar Almahamoudou³,Sanogo Koualy³,Keita Sekouba³,Kone Daouda³,Diarra Kalifa³,Djimde Moussa³,Keita Mohamed⁴,Brown Joelle²,Roh Michelle E¹²,Hwang Jimee¹⁵,Pett Helmi⁶⁷,Murphy Maxwell⁸,Niemi Mikko⁷,Greenhouse Bryan⁸,Bousema Teun⁶⁹,Gosling Roly¹²,Dicko Alassane³

Affiliation:

1. Malaria Elimination Initiative, Global Health Group, San Francisco

2. Department of Epidemiology and Biostatistics, San Francisco

3. Malaria Research and Training Centre, Faculty of Pharmacy and Faculty of Medicine and Dentistry, University of Science, Techniques and Technologies of Bamako

4. National University Hospital of Point G, Bamako, Mali

5. President’s Malaria Initiative, Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia

6. Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands

7. Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Finland

8. School of Medicine, University of California, San Francisco

9. Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, United Kingdom

Funder

Bill and Melinda Gates Foundation

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/217/8/1298/25090480/jiy014.pdf